Illumina Partners with Taiwan’s Leading AI Healthcare Innovators to Launch the Next-Generation AMG AI Genomic Precision Medicine Platform

Under the support of the Southern Taiwan Science Park Administration (STSPA), global sequencing leader Illumina has joined forces with Taiwan’s AI healthcare innovators—Marketech International / Smart Group Solutions (SGSC), Biomedica, along with multinational partners NTT DATA Taiwan and Hewlett Packard Enterprise (HPE)—to introduce the new “AI NGS AMG Intelligent Precision Medicine Solution” at the 2025 Taiwan Healthcare Expo. The collaboration marks a milestone in building an international-grade, AI-driven clinical genomics ecosystem.

Illumina’s APAC Commercial Director, Yvonne Wang, highlighted Taiwan’s dual advantages in biomedical R&D and AI innovation. “By partnering with Marketech/SGSC and Biomedica, we are integrating the full value chain—from automation to AI analytics—transforming genomic data from research output into real-world clinical decision support.”

The joint showcase features the latest generation Illumina × AMG (AI MetaLife Genomics) platform, which integrates advanced AI algorithms, DigitalLife Modeling, and intelligent automated laboratory workflows to deliver a fully unified pipeline spanning sample processing, sequencing, and AI-powered clinical interpretation.

The AMG architecture brings together four core components:
• Illumina’s clinical-grade oncology sequencing panels for comprehensive cancer detection.
• Marketech/SGSC’s Auto X-Series automated laboratory systems for nucleic acid extraction, pipetting, and purification.
• Biomedica’s AIVITA Nucleo Data Analyzer, an AI engine built with large language models (LLMs) and NVIDIA GPU acceleration to automatically identify gene fusions, RNA expression signatures, and mutational profiles, producing rapid and structured clinical reports.
• A unified workflow that connects sequencing output to actionable insights for precision oncology practice.

Biomedica CEO Dr. Omni Zhang emphasized that AI is becoming the backbone of precision medicine, and Illumina remains the gold standard in global sequencing technology. “This collaboration moves AI beyond software analytics. It embeds intelligence directly into every step of the NGS laboratory, enabling true end-to-end ‘gene-to-clinic’ decision-making.”

International partners further strengthen the system’s scalability and compliance readiness:
• NTT DATA Taiwan will support multi-institutional clinical data exchange and governance frameworks.
• HPE will provide high-performance, resilient computing infrastructure purpose-built for clinical NGS and AI workloads.

With STSPA’s strategic facilitation, this initiative is positioned as a flagship example of Taiwan’s AI healthcare globalization. As the global precision medicine market accelerates, the partnership between Illumina and Taiwan’s leading AI ecosystem underscores a powerful convergence of world-class sequencing technology and home-grown AI innovation.

Illumina and its Taiwan partners will continue expanding AI-enabled clinical genomics applications to strengthen Taiwan’s footprint on the global precision medicine stage.

Ref: https://news.gbimonthly.com/tw/article/show.php?num=82169